The CanAg CA19-9 EIA is based on a mouse monoclonal antibody, C192, highly specific for the sialyl Lewisa epitope, also known as CA19-9 antigen1.
In adults, the epitope is typically expressed in trace amounts on mucosal cells of gastrointestinal epithelia. In patients with malignant disease, the epitope may appear associated with high molecular weight mucin in blood. Assays for CA19-9 are frequently used to monitor gastrointestinal malignancies such as pancreatic, gall bladder, gastric, and colorectal cancers2, 3.
Rye P. D. et al., (1998) Summary report on the ISOBM TD-6 workshop: Analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreaux, Switzerland; September 19-24 1997. Tumor Biol. 19:390-420.
Eskelinen M., and Haglund U. (1999) Developments in serologic detection of human pancreatic adenocarcinoma. Scand J Gastroenterol. 34: 833-844.
Hammarström S., and Stigbrand T. (2002) Gastric Cancer. In “Tumor markers, Physiology, Pathobiology, Technology and Clinical Applications” Eds. Diamandis E. P. et al., AACC Press, Washington pp 375-379.
CanAg CA19-9 EIA
For 96 determinations
Please contact your local Fujirebio representative for the availability of this product in your country.
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.